MCID: EXT027
MIFTS: 36

Extrahepatic Bile Duct Adenocarcinoma

Categories: Cancer diseases, Gastrointestinal diseases, Liver diseases

Aliases & Classifications for Extrahepatic Bile Duct Adenocarcinoma

MalaCards integrated aliases for Extrahepatic Bile Duct Adenocarcinoma:

Name: Extrahepatic Bile Duct Adenocarcinoma 12 15
Adenocarcinoma of the Extrahepatic Bile Duct 12 73
Adenocarcinoma of Extrahepatic Bile Duct 12

Classifications:



External Ids:

Disease Ontology 12 DOID:3495
NCIt 50 C7975
UMLS 73 C0279659

Summaries for Extrahepatic Bile Duct Adenocarcinoma

Disease Ontology : 12 An extrahepatic bile duct carcinoma that derives from epithelial cells of glandular origin.

MalaCards based summary : Extrahepatic Bile Duct Adenocarcinoma, also known as adenocarcinoma of the extrahepatic bile duct, is related to papillary extrahepatic bile duct adenocarcinoma and ureter small cell carcinoma, and has symptoms including abdominal pain, icterus and nausea. An important gene associated with Extrahepatic Bile Duct Adenocarcinoma is SYP (Synaptophysin), and among its related pathways/superpathways are Neuroscience and Cell adhesion molecules (CAMs). The drugs Gemcitabine and Capecitabine have been mentioned in the context of this disorder. Affiliated tissues include liver, pancreas and lymph node.

Related Diseases for Extrahepatic Bile Duct Adenocarcinoma

Diseases related to Extrahepatic Bile Duct Adenocarcinoma via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 141)
# Related Disease Score Top Affiliating Genes
1 papillary extrahepatic bile duct adenocarcinoma 12.3
2 ureter small cell carcinoma 10.7 ENO2 SYP
3 malignant sertoli cell tumor 10.7 ENO2 SYP
4 urinary bladder small cell neuroendocrine carcinoma 10.7 ENO2 SYP
5 auditory system cancer 10.7 ENO2 SYP
6 sinonasal undifferentiated carcinoma 10.7 ENO2 SYP
7 pancreatic somatostatinoma 10.7 ENO2 SYP
8 small cell carcinoma of the bladder 10.7 ENO2 SYP
9 papillary tumor of the pineal region 10.7 ENO2 SYP
10 middle ear adenoma 10.7 ENO2 SYP
11 ovarian carcinosarcoma 10.7 ENO2 SYP
12 pulmonary large cell neuroendocrine carcinoma 10.7 ENO2 SYP
13 atypical follicular adenoma 10.7 ENO2 SYP
14 central nervous system primitive neuroectodermal neoplasm 10.7 ENO2 SYP
15 cerebellum cancer 10.7 ENO2 SYP
16 subependymal glioma 10.7 ENO2 SYP
17 olfactory nerve neoplasm 10.7 ENO2 SYP
18 cerebral neuroblastoma 10.7 ENO2 SYP
19 cauda equina neoplasm 10.7 ENO2 SYP
20 extraosseous chondrosarcoma 10.7 ENO2 SYP
21 benign ependymoma 10.7 ENO2 SYP
22 malignant teratoma 10.7 ENO2 SYP
23 astroblastoma 10.7 ENO2 SYP
24 cerebral ventricle cancer 10.7 ENO2 SYP
25 cerebrum cancer 10.7 ENO2 SYP
26 pineal gland cancer 10.7 ENO2 SYP
27 melanotic neuroectodermal tumor 10.7 ENO2 SYP
28 nodular ganglioneuroblastoma 10.7 ENO2 SYP
29 supratentorial cancer 10.7 ENO2 SYP
30 mucinous ovarian cystadenoma 10.7 ENO2 SYP
31 pineocytoma 10.6 ENO2 SYP
32 respiratory system benign neoplasm 10.6 ENO2 SYP
33 desmoplastic small round cell tumor 10.6 ENO2 SYP
34 carcinoid tumors, intestinal 10.6 ENO2 SYP
35 bone benign neoplasm 10.6 ENO2 SYP
36 meningeal melanomatosis 10.6 ENO2 SYP
37 papillary ependymoma 10.6 ENO2 SYP
38 extraskeletal ewing sarcoma 10.6 ENO2 SYP
39 connective tissue benign neoplasm 10.6 ENO2 SYP
40 glomus tumor 10.6 ENO2 SYP
41 esophageal neuroendocrine tumor 10.6 NCAM1 SYP
42 intraocular retinoblastoma 10.6 ENO2 SYP
43 sclerosing hemangioma 10.6 ENO2 SYP
44 ovarian large-cell neuroendocrine carcinoma 10.6 NCAM1 SYP
45 subependymal giant cell astrocytoma 10.6 ENO2 SYP
46 central neurocytoma 10.6 ENO2 SYP
47 perivascular epithelioid cell tumor 10.6 MME SYP
48 hypoganglionosis 10.6 NCAM1 SYP
49 carcinoid syndrome 10.6 ENO2 SYP
50 pancreatic endocrine carcinoma 10.6 NCAM1 SYP

Graphical network of the top 20 diseases related to Extrahepatic Bile Duct Adenocarcinoma:



Diseases related to Extrahepatic Bile Duct Adenocarcinoma

Symptoms & Phenotypes for Extrahepatic Bile Duct Adenocarcinoma

UMLS symptoms related to Extrahepatic Bile Duct Adenocarcinoma:


abdominal pain, icterus, nausea, pruritus, vomiting, malaise

Drugs & Therapeutics for Extrahepatic Bile Duct Adenocarcinoma

Drugs for Extrahepatic Bile Duct Adenocarcinoma (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show all 45)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Gemcitabine Approved Phase 3,Phase 2,Phase 1 95058-81-4 60750
2
Capecitabine Approved, Investigational Phase 3,Phase 2 154361-50-9 60953
3
Oxaliplatin Approved, Investigational Phase 3,Phase 1 61825-94-3 5310940 9887054 43805 6857599
4 Immunosuppressive Agents Phase 3,Phase 2,Phase 1
5 Anti-Infective Agents Phase 3,Phase 2,Phase 1
6 Antimetabolites Phase 3,Phase 2,Phase 1
7 Antiviral Agents Phase 3,Phase 2,Phase 1
8 Antimetabolites, Antineoplastic Phase 3,Phase 2,Phase 1
9 Liver Extracts Phase 3,Phase 2,Phase 1
10
Fluorouracil Approved Phase 2 51-21-8 3385
11
Pancrelipase Approved, Investigational Phase 2,Phase 1 53608-75-6
12
Levoleucovorin Approved, Investigational Phase 2 68538-85-2
13
Sorafenib Approved, Investigational Phase 2 284461-73-0 216239 406563
14
Melphalan Approved Phase 2 148-82-3 4053 460612
15
Trastuzumab Approved, Investigational Phase 2 180288-69-1 9903
16
Bortezomib Approved, Investigational Phase 2 179324-69-7 387447 93860
17
leucovorin Approved, Nutraceutical Phase 2 58-05-9 143 6006
18
Nicotinamide Approved, Investigational, Nutraceutical Phase 2 98-92-0 936
19
Niacin Approved, Investigational, Nutraceutical Phase 2 59-67-6 938
20
Folic Acid Approved, Nutraceutical, Vet_approved Phase 2 59-30-3 6037
21 Pancreatic Polypeptide Investigational Phase 2 59763-91-6
22 pancreatin Phase 2,Phase 1
23 Antidotes Phase 2
24 Protective Agents Phase 2
25 Calcium, Dietary Phase 2
26
Erlotinib Hydrochloride Phase 2,Phase 1 183319-69-9 176871
27 Alkylating Agents Phase 2
28 Micronutrients Phase 2
29 Nicotinic Acids Phase 2
30 Trace Elements Phase 2
31 Vitamin B Complex Phase 2
32 Vitamins Phase 2
33 Protein Kinase Inhibitors Phase 2,Phase 1
34 Antineoplastic Agents, Alkylating Phase 2
35 Adjuvants, Immunologic Phase 2
36 Freund's Adjuvant Phase 2
37 Vaccines Phase 2
38 Cola Nutraceutical Phase 2,Phase 1
39 Folate Nutraceutical Phase 2
40 Vitamin B3 Nutraceutical Phase 2
41 Vitamin B9 Nutraceutical Phase 2
42
Azacitidine Approved, Investigational Phase 1 320-67-2 9444
43 Antibodies Phase 1
44 Immunoglobulins Phase 1
45 Antibodies, Monoclonal Phase 1

Interventional clinical trials:

(show all 18)
# Name Status NCT ID Phase Drugs
1 Gemcitabine Hydrochloride and Oxaliplatin or Observation in Treating Patients With Biliary Tract Cancer That Has Been Removed by Surgery Completed NCT01313377 Phase 3 gemcitabine hydrochloride;oxaliplatin
2 Gemcitabine With or Without Capecitabine in Treating Patients With Locally Advanced, Unresectable, or Metastatic Biliary Cancer Terminated NCT00658593 Phase 3 capecitabine;gemcitabine hydrochloride
3 Chemotherapy in Treating Patients With Locally Advanced or Metastatic Cancer of the Pancreas or Bile Duct Unknown status NCT00010088 Phase 2 fluorouracil;gemcitabine hydrochloride;leucovorin calcium
4 Sorafenib Tosylate and Erlotinib Hydrochloride in Treating Patients With Locally Advanced, Unresectable, or Metastatic Gallbladder Cancer or Cholangiocarcinoma Completed NCT01093222 Phase 2 Erlotinib Hydrochloride;Sorafenib Tosylate
5 Trastuzumab in Treating Patients With Locally Advanced or Metastatic Gallbladder Cancer or Bile Duct Cancer That Cannot Be Removed by Surgery Completed NCT00478140 Phase 2
6 S0514 Sorafenib in Treating Patients With Unresectable or Metastatic Gallbladder Cancer or Cholangiocarcinoma Completed NCT00238212 Phase 2 sorafenib tosylate
7 Adjuvant Palliative Capecitabine and Gemcitabine in Treating Patients With Locally Advanced or Metastatic Biliary Tract Cancer Completed NCT00073905 Phase 2 capecitabine plus gemcitabine
8 Hepatic Arterial Infusion of Melphalan With Hepatic Perfusion in Treating Patients With Unresectable Liver Cancer Completed NCT00096083 Phase 2 isolated perfusion;melphalan
9 S0202 Gemcitabine and Capecitabine for Unresectable Locally Advanced Metastatic Gallbladder Cancer or Cholangiocarcinoma Completed NCT00033540 Phase 2 capecitabine;gemcitabine hydrochloride
10 Bortezomib in Treating Patients With Unresectable Locally Advanced or Metastatic Adenocarcinoma of the Bile Duct or Gallbladder Terminated NCT00085410 Phase 2 bortezomib
11 Vaccine Therapy in Treating Patients With Cancer of the Gastrointestinal Tract Terminated NCT00012246 Phase 2
12 Gemcitabine and Radiation Therapy in Treating Patients With Locally Advanced Upper Gastrointestinal Cancer Completed NCT00544193 Phase 1 gemcitabine hydrochloride
13 Gemcitabine Hydrochloride, Oxaliplatin, and Erlotinib Hydrochloride in Treating Patients With Advanced Biliary Tract Cancer, Pancreatic Cancer, Duodenal Cancer, or Ampullary Cancer Completed NCT00987766 Phase 1 erlotinib hydrochloride;gemcitabine hydrochloride;oxaliplatin
14 RAV12 in Treating Patients With Metastatic or Recurrent Adenocarcinoma Completed NCT00101972 Phase 1
15 Oxaliplatin, Gemcitabine, Erlotinib, and Radiation Therapy in Treating Patients With Unresectable and/or Metastatic Pancreatic Cancer or Biliary Tract Cancer Completed NCT00266097 Phase 1 erlotinib hydrochloride;gemcitabine hydrochloride;oxaliplatin;gemcitabine hydrochloride;Oxaliplatin
16 Gene Therapy in Treating Patients With Cancer Completed NCT00004178 Phase 1
17 BCX-1777 in Treating Patients With Refractory Cancer Completed NCT00073944 Phase 1 forodesine hydrochloride
18 Guadecitabine and Durvalumab in Treating Patients With Advanced Liver, Pancreatic, Bile Duct, or Gallbladder Cancer Recruiting NCT03257761 Phase 1 Guadecitabine

Search NIH Clinical Center for Extrahepatic Bile Duct Adenocarcinoma

Genetic Tests for Extrahepatic Bile Duct Adenocarcinoma

Anatomical Context for Extrahepatic Bile Duct Adenocarcinoma

MalaCards organs/tissues related to Extrahepatic Bile Duct Adenocarcinoma:

41
Liver, Pancreas, Lymph Node

Publications for Extrahepatic Bile Duct Adenocarcinoma

Articles related to Extrahepatic Bile Duct Adenocarcinoma:

# Title Authors Year
1
Hepatoid Adenocarcinoma of the Extrahepatic Bile Duct in a Patient with Polysplenia Syndrome. ( 28202861 )
2017
2
Differentiation grade for extrahepatic bile duct adenocarcinoma: Assessed by diffusion-weighted imaging at 3.0-T MR. ( 27776649 )
2016
3
Adequate lymph node assessment for extrahepatic bile duct adenocarcinoma. ( 20224368 )
2010
4
Extrahepatic bile duct adenocarcinoma: patients at high-risk for local recurrence treated with surgery and adjuvant chemoradiation have an equivalent overall survival to patients with standard-risk treated with surgery alone. ( 18754070 )
2008
5
Papillary adenocarcinoma of the extrahepatic bile duct in a Holstein cow. ( 15657275 )
2005

Variations for Extrahepatic Bile Duct Adenocarcinoma

Expression for Extrahepatic Bile Duct Adenocarcinoma

Search GEO for disease gene expression data for Extrahepatic Bile Duct Adenocarcinoma.

Pathways for Extrahepatic Bile Duct Adenocarcinoma

Pathways related to Extrahepatic Bile Duct Adenocarcinoma according to GeneCards Suite gene sharing:

# Super pathways Score Top Affiliating Genes
1 12.14 ENO2 NCAM1 SYP
2 11.59 CDH1 NCAM1 SDC1
3 11.42 CDH1 NCAM1 SDC1
4 11.2 MME NCAM1 SDC1
5 11.13 MME SDC1
6 11.04 CDH1 NCAM1
7 10.97 CDH1 SDC1
8 10.67 CDH1 MME NCAM1

GO Terms for Extrahepatic Bile Duct Adenocarcinoma

Cellular components related to Extrahepatic Bile Duct Adenocarcinoma according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 neuron projection terminus GO:0044306 8.62 MME SYP

Sources for Extrahepatic Bile Duct Adenocarcinoma

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 ExPASy
19 FMA
28 GO
29 GTR
30 HGMD
31 HMDB
32 HPO
33 ICD10
34 ICD10 via Orphanet
35 ICD9CM
36 IUPHAR
37 KEGG
38 LifeMap
40 LOVD
42 MedGen
44 MeSH
45 MESH via Orphanet
46 MGI
49 NCI
50 NCIt
51 NDF-RT
54 NINDS
55 Novoseek
57 OMIM
58 OMIM via Orphanet
62 PubMed
64 QIAGEN
69 SNOMED-CT via HPO
70 SNOMED-CT via Orphanet
71 TGDB
72 Tocris
73 UMLS
74 UMLS via Orphanet
Content
Loading form....